Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.69 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.69 |
| ▸ | TAF1 | P21675 | 1/20 | 0.69 |
| ▸ | BRD2 | P25440 | 1/20 | 0.69 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.69 |
| ▸ | EP300 | Q09472 | 1/20 | 0.69 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.69 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.69 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.69 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16225573 | 0.90 | BRD4 (0.69) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225472 | 0.89 | BRD4 (0.67) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225598 | 0.88 | BRD4 (0.66) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225595 | 0.87 | BRD4 (0.65) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225696 | 0.84 | BRD4 (0.66) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225360 | 0.83 | BRD4 (0.68) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225532 | 0.82 | BRD4 (0.82) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16225268 | 0.81 | BRD4 (1.00) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL29881459 | 0.81 | BRD4 (1.00) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL16230658 | 0.81 | BRD4 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018106444-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106433-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180153868-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153868-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153867-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2994469-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Gilead Sciences, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014182929-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014182929-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 728/4885TAF1 261/4885 |
| US-20180153867-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | BRDT, BRD4, BRD2 | BRD4 2/4885TRIM24 825/4885TAF1 2001/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 728/4885TAF1 261/4885 |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 773/4885TAF1 284/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 717/4885TAF1 281/4885 |
| US-20180153868-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | BRDT, BRD4, BRD2 | BRD4 2/4885TRIM24 607/4885TAF1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.